138 related articles for article (PubMed ID: 38520765)
1. Assessment for 11q and other chromosomal aberrations in large B-cell/high-grade B cell lymphomas of germinal center phenotype lacking BCL2 expression.
Ho CC; Naresh K; Liu Y; Wu Y; Gopal AK; Eckel AM
Cancer Genet; 2024 Jun; 284-285():30-33. PubMed ID: 38520765
[TBL] [Abstract][Full Text] [Related]
2. A Diagnostic Approach to the Identification of Burkitt-like Lymphoma With 11q Aberration in Aggressive B-Cell Lymphomas.
Horn H; Kalmbach S; Wagener R; Staiger AM; Hüttl K; Mottok A; Bens S; Traverse-Glehen A; Fontaine J; Siebert R; Rosenwald A; Ott G
Am J Surg Pathol; 2021 Mar; 45(3):356-364. PubMed ID: 33136583
[TBL] [Abstract][Full Text] [Related]
3. Burkitt-like lymphoma with 11q aberration: a germinal center-derived lymphoma genetically unrelated to Burkitt lymphoma.
Gonzalez-Farre B; Ramis-Zaldivar JE; Salmeron-Villalobos J; Balagué O; Celis V; Verdu-Amoros J; Nadeu F; Sábado C; Ferrández A; Garrido M; García-Bragado F; de la Maya MD; Vagace JM; Panizo CM; Astigarraga I; Andrés M; Jaffe ES; Campo E; Salaverria I
Haematologica; 2019 Sep; 104(9):1822-1829. PubMed ID: 30733272
[TBL] [Abstract][Full Text] [Related]
4. miR expression in MYC-negative DLBCL/BL with partial trisomy 11 is similar to classical Burkitt lymphoma and different from diffuse large B-cell lymphoma.
Zajdel M; Rymkiewicz G; Chechlinska M; Blachnio K; Pienkowska-Grela B; Grygalewicz B; Goryca K; Cieslikowska M; Bystydzienski Z; Swoboda P; Walewski J; Siwicki JK
Tumour Biol; 2015 Jul; 36(7):5377-88. PubMed ID: 25677902
[TBL] [Abstract][Full Text] [Related]
5. B-cell lymphomas with concurrent IGH-BCL2 and MYC rearrangements are aggressive neoplasms with clinical and pathologic features distinct from Burkitt lymphoma and diffuse large B-cell lymphoma.
Snuderl M; Kolman OK; Chen YB; Hsu JJ; Ackerman AM; Dal Cin P; Ferry JA; Harris NL; Hasserjian RP; Zukerberg LR; Abramson JS; Hochberg EP; Lee H; Lee AI; Toomey CE; Sohani AR
Am J Surg Pathol; 2010 Mar; 34(3):327-40. PubMed ID: 20118770
[TBL] [Abstract][Full Text] [Related]
6. High-grade B-cell lymphoma with concurrent MYC rearrangement and 11q aberrations: clinicopathologic, cytogenetic, and molecular characterization of 4 cases.
Shestakova A; Shao L; Smith LB; Ryan R; Bedell V; Murata-Collins J; Zhang W; Perry AM; Song JY
Hum Pathol; 2023 Jun; 136():34-43. PubMed ID: 36997031
[TBL] [Abstract][Full Text] [Related]
7. Genetic and phenotypic characterisation of HIV-associated aggressive B-cell non-Hodgkin lymphomas, which do not occur specifically in this population: diagnostic and prognostic implications.
Baptista MJ; Tapia G; Muñoz-Marmol AM; Muncunill J; Garcia O; Montoto S; Gribben JG; Calaminici M; Martinez A; Veloza L; Martínez-Trillos A; Aldamiz T; Menarguez J; Terol MJ; Ferrandez A; Alcoceba M; Briones J; González-Barca E; Climent F; Muntañola A; Moraleda JM; Provencio M; Abrisqueta P; Abella E; Colomo L; García-Ballesteros C; Garcia-Caro M; Sancho JM; Ribera JM; Mate JL; Navarro JT
Histopathology; 2022 Dec; 81(6):826-840. PubMed ID: 36109172
[TBL] [Abstract][Full Text] [Related]
8. Application of 2016 WHO classification in the diagnosis of paediatric high-grade
Zhang L; Brown LE; Bowen LM; McCarthy LC; Cooley LD; Repnikova E; Gener MA; Garola R; August KJ; Hays JA; Zwick DL; Li W
J Clin Pathol; 2020 Sep; 73(9):563-570. PubMed ID: 31964683
[TBL] [Abstract][Full Text] [Related]
9. B-cell lymphomas with MYC/8q24 rearrangements and IGH@BCL2/t(14;18)(q32;q21): an aggressive disease with heterogeneous histology, germinal center B-cell immunophenotype and poor outcome.
Li S; Lin P; Fayad LE; Lennon PA; Miranda RN; Yin CC; Lin E; Medeiros LJ
Mod Pathol; 2012 Jan; 25(1):145-56. PubMed ID: 22002575
[TBL] [Abstract][Full Text] [Related]
10. BCL2 gene aberration as an IPI-independent marker for poor outcome in non-germinal-centre diffuse large B cell lymphoma.
Obermann EC; Csato M; Dirnhofer S; Tzankov A
J Clin Pathol; 2009 Oct; 62(10):903-7. PubMed ID: 19783718
[TBL] [Abstract][Full Text] [Related]
11. Emerging entities: high-grade/large B-cell lymphoma with 11q aberration, large B-cell lymphoma with IRF4 rearrangement, and new molecular subgroups in large B-cell lymphomas. A report of the 2022 EA4HP/SH lymphoma workshop.
Quintanilla-Martinez L; Laurent C; Soma L; Ng SB; Climent F; Ondrejka SL; Zamo A; Wotherspoon A; de Leval L; Dirnhofer S; Leoncini L
Virchows Arch; 2023 Sep; 483(3):281-298. PubMed ID: 37555980
[TBL] [Abstract][Full Text] [Related]
12. Experience with provisional WHO-entities large B-cell lymphoma with IRF4-rearrangement and Burkitt-like lymphoma with 11q aberration in paediatric patients of the NHL-BFM group.
Au-Yeung RKH; Arias Padilla L; Zimmermann M; Oschlies I; Siebert R; Woessmann W; Burkhardt B; Klapper W
Br J Haematol; 2020 Sep; 190(5):753-763. PubMed ID: 32239695
[TBL] [Abstract][Full Text] [Related]
13. Molecular determinants of clinical outcomes in a real-world diffuse large B-cell lymphoma population.
Alduaij W; Collinge B; Ben-Neriah S; Jiang A; Hilton LK; Boyle M; Meissner B; Chong L; Miyata-Takata T; Slack GW; Farinha P; Craig JW; Lytle A; Savage KJ; Villa D; Gerrie AS; Freeman CL; Gascoyne RD; Connors JM; Morin RD; Sehn LH; Mungall AJ; Steidl C; Scott DW
Blood; 2023 May; 141(20):2493-2507. PubMed ID: 36302166
[TBL] [Abstract][Full Text] [Related]
14. The 11q-Gain/Loss Aberration Occurs Recurrently in MYC-Negative Burkitt-like Lymphoma With 11q Aberration, as Well as MYC-Positive Burkitt Lymphoma and MYC-Positive High-Grade B-Cell Lymphoma, NOS.
Grygalewicz B; Woroniecka R; Rymkiewicz G; Rygier J; Borkowska K; Kotyl A; Blachnio K; Bystydzienski Z; Nowakowska B; Pienkowska-Grela B
Am J Clin Pathol; 2017 Dec; 149(1):17-28. PubMed ID: 29272887
[TBL] [Abstract][Full Text] [Related]
15. [Fluorescence in situ hybridization in the diagnosis of aggressive B-cell lymphomas].
Gerhard-Hartmann E; Rosenwald A
Pathologe; 2020 Nov; 41(6):574-581. PubMed ID: 32909092
[TBL] [Abstract][Full Text] [Related]
16. MYC single-hit large B-cell lymphoma: clinicopathologic difference from MYC-negative large B-cell lymphoma and MYC double-hit/triple-hit lymphoma.
Cho YA; Hyeon J; Lee H; Cho J; Kim SJ; Kim WS; Ko YH
Hum Pathol; 2021 Jul; 113():9-19. PubMed ID: 33771538
[TBL] [Abstract][Full Text] [Related]
17. Clinical Significance of
Ting CY; Chang KM; Kuan JW; Sathar J; Chew LP; Wong OJ; Yusuf Y; Wong L; Samsudin AT; Pana MNBM; Lee SK; Gopal NSR; Puri R; Ong TC; Bahari SK; Goh AS; Teoh CS
Int J Med Sci; 2019; 16(4):556-566. PubMed ID: 31171907
[No Abstract] [Full Text] [Related]
18. Aggressive B-cell lymphoma cases with 11q aberration patterns indicate a spectrum beyond Burkitt-like lymphoma.
Gebauer N; Witte HM; Merz H; Oschlies I; Klapper W; Caliebe A; Tharun L; Spielmann M; von Bubnoff N; Feller AC; Murga Penas EM
Blood Adv; 2021 Dec; 5(23):5220-5225. PubMed ID: 34500469
[TBL] [Abstract][Full Text] [Related]
19. The mutational landscape of Burkitt-like lymphoma with 11q aberration is distinct from that of Burkitt lymphoma.
Wagener R; Seufert J; Raimondi F; Bens S; Kleinheinz K; Nagel I; Altmüller J; Thiele H; Hübschmann D; Kohler CW; Nürnberg P; Au-Yeung R; Burkhardt B; Horn H; Leoncini L; Jaffe ES; Ott G; Rymkiewicz G; Schlesner M; Russell RB; Klapper W; Siebert R
Blood; 2019 Feb; 133(9):962-966. PubMed ID: 30567752
[TBL] [Abstract][Full Text] [Related]
20. [Classification of aggressive B-cell lymphomas : News and open questions].
Rosenwald A; Menter T; Dirnhofer S
Pathologie (Heidelb); 2023 May; 44(3):166-172. PubMed ID: 36918411
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
